Close Menu

NEW YORK (360Dx) – Oxford Immunotec reported Tuesday that its third quarter revenues increased 17 percent year over year, driven by continued growth in both its tuberculosis and tick-borne disease testing businesses.

For the three months ended Sept. 30, Oxford Immunotec reported total revenues of $30.4 million, up from $26.1 million a year ago, and beating analysts' average estimate of $30.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.